Welcome to our dedicated page for OSR Holdings news (Ticker: OSRH), a resource for investors and traders seeking the latest updates and insights on OSR Holdings stock.
OSR Holdings, Inc. (NASDAQ: OSRH) generates news across multiple areas of healthcare and biotechnology, reflecting its role as a global healthcare holding company focused on immuno-oncology, regenerative biologics, and medical device technologies. The company’s news flow often centers on developments at its key subsidiaries, strategic licensing discussions, clinical data updates, and corporate finance activities.
One major stream of OSR Holdings news relates to Vaximm AG, its Swiss-German immuno-oncology subsidiary. Press releases have detailed Vaximm’s proprietary orally administered T-cell vaccination platform, the clinical progress of lead candidate VXM01 targeting VEGFR-2, and negotiations with BCM Europe AG and affiliated investment vehicles for potential global exclusive licensing arrangements. Updates have covered non-binding and binding term sheets, proposed upfront and milestone payment structures, royalty pass-through mechanisms, and plans to obtain independent fairness opinions, providing insight into how OSR Holdings seeks to unlock value from its immunotherapy assets.
Another important category of news involves Woori IO Co., Ltd., a South Korea-based medical-device company focused on noninvasive glucose monitoring. OSR Holdings has issued releases on the signing and approval of a definitive share exchange agreement under which Woori IO becomes a wholly owned subsidiary of its Korean affiliate, as well as on Woori IO’s collaborations with Samsung Electronics on proof-of-concept studies. News items have also summarized pilot study results for the Glucheck blood glucose measurement system conducted with Korea University Guro Hospital, highlighting accuracy, precision, and ISO 15197:2013 compliance.
Investors following OSRH news will also see announcements about virtual investor events, conference presentations, equity financing arrangements, and Nasdaq listing matters, including notices regarding minimum bid price compliance. This dedicated news page allows readers to track OSR Holdings’ evolving portfolio, licensing initiatives, clinical milestones, and capital markets updates in one place, with new items added as the company furnishes press releases and related SEC communications.
OSR Holdings (NASDAQ: OSRH) has appointed Dr. Andreas Niethammer as Chief Medical Officer of its subsidiary Vaximm AG. Dr. Niethammer, who co-founded Vaximm, is returning to lead the clinical development of the company's oral T-cell activator platform, including the clinical-stage candidate VXM01.
With over 20 years of experience in cancer immunotherapy, Dr. Niethammer brings significant expertise from leadership roles at companies like Fate Therapeutics, NantKwest, and Pfizer. He originally developed the concept of oral T-cell vaccination at the Scripps Research Institute and has successfully advanced VXM01 into clinical trials for pancreatic cancer and glioblastoma.
OSR Holdings (NASDAQ:OSRH) has unveiled plans for a $50 million security token offering (STO) under Regulation D in H2 2025. The company will launch OSRT, a security token representing OSRH equity exposure, accepting Bitcoin (BTC), Tether (USDT), and Taekwondo Access Credit (TAC) as subscription currencies.
The initiative is part of OSRH's broader strategy to build a $100 million Bitcoin and USDT reserve, supported by an $80 million equity line of credit (ELOC) from White Lion GBM Innovation Fund. BCM Europe AG, OSRH's largest shareholder, will convert its TAC holdings to BTC/USDT before participating in the offering to ensure compliance and avoid insider trading concerns.
OSR Holdings (NASDAQ: OSRH) has unveiled plans for a $50 million security token offering (STO) under Regulation D in the second half of 2025. The company will launch OSRT, a security token representing equity exposure, accepting Bitcoin (BTC), Tether (USDT), and Taekwondo Access Credit (TAC) as subscription currencies.
The strategic roadmap includes restrictions on BCM Europe AG, OSR's largest shareholder, from directly using TAC for subscription. The company aims to build a $100 million Bitcoin and USDT reserve, supported by both the STO and an $80 million equity line of credit (ELOC) from White Lion GBM Innovation Fund. This initiative aligns with OSR's blockchain-based capital strategy and its focus on integrating decentralized finance with healthcare innovation.
OSR Holdings (NASDAQ: OSRH) has signed a Memorandum of Understanding (MOU) with BCM Europe AG and Taekwondo Cooperative (TKD Coop) to develop a security token called the "OSRH Token". The token will accept Bitcoin (BTC), Tether (USDT), and Taekwondo Access Credit (TAC) as subscription currencies.
The initiative aims to enhance crypto-based liquidity access and launch crypto treasury strategies. BCM Europe AG, OSRH's largest shareholder, intends to contribute its TAC token rights, reserve, and infrastructure to OSRH. TKD Coop, which has been using the TAC token since 2021, will continue leading blockchain adoption in the Taekwondo community. The MOU has a three-month term for finalizing the legal and technical framework.
Darnatein, a subsidiary of OSR Holdings (NASDAQ: OSRH), will present scientific data at the 14th International Bone Morphogenetic Protein (BMP) Conference from May 2-6, 2025. CEO Dr. Senyon Choe will showcase the company's proprietary platform technology and two key biologic candidates: DRT-101 for joint cartilage regeneration and DRT-102 for spinal bone repair.
The company has achieved significant milestones, including preclinical validation of both candidates demonstrating safety and enhanced tissue regeneration. Darnatein is conducting IND-enabling studies with BioToxTech and UC San Diego, working towards IND submissions to Korean MFDS and U.S. FDA for DRT-101.
Darnatein, a subsidiary of OSR Holdings (NASDAQ: OSRH), has secured a patent in China for its innovative protein-based osteoarthritis treatment technology. The patent covers their lead drug candidate DRT-101, which utilizes AI-enhanced protein structure generation to create a novel chimeric protein combining BMP7 and Activin proteins.
The technology has shown enhanced therapeutic efficacy and safety in studies conducted at UC San Diego between 2020-2024. This marks Darnatein's first international patent following their South Korean registration, with pending applications in the EU and US through the PCT route.
The global osteoarthritis treatment market, valued at $8.9 billion in 2023, is projected to reach $16.1 billion by 2032, growing at 7% annually. Darnatein aims to initiate Phase 1 clinical trials for DRT-101 later this year, targeting disease modification rather than just symptom management in osteoarthritis treatment.
OSR Holdings (NASDAQ: OSRH) has entered into a significant $80 million Common Stock Purchase Agreement with White Lion GBM Innovation Fund. The agreement gives OSR the right, but not the obligation, to sell common stock to Innovation Fund over time, aimed at funding their glioblastoma therapy development.
The company's key focus includes advancing Vaximm, a Swiss-based biotech developing a novel GBM vaccine (VXM01) for glioblastoma treatment. This strategic partnership connects OSR with Innovate GBM's ecosystem, a 501(c)(3) nonprofit that unites scientists, clinicians, investors, and patient advocates to streamline collaboration in glioblastoma R&D.
The collaboration is expected to accelerate OSR's Vaximm immunotherapy platform development while leveraging Innovate GBM's network of researchers, regulatory experts, and policymakers to enhance innovation in glioblastoma treatment.
Vaximm AG, an OSR Holdings subsidiary, has announced final data from its Phase 2a clinical trial evaluating VXM01 in combination with avelumab for recurrent glioblastoma (GBM) treatment. The trial demonstrated:
- Good safety profile with mostly mild to moderate events
- 12.0% objective response rate in non-resected patients
- Median overall survival of 11.1 months
- Median time to progression of 2.7 months
The study (n=25) showed promising results compared to typical GBM prognosis. No serious adverse events were attributed to VXM01, while 81.8% were related to the disease itself. In resected patients, overall survival ranged from 2.2 to 46.5 months. The trial identified potential biomarkers for VXM01-mediated tumor response, supporting further investigation of the treatment combination.
OSR Holdings (NASDAQ: OSRH) has appointed Dr. Constance Höfer as its new Chief Scientific Officer (CSO). Dr. Höfer brings over 20 years of experience in drug development, specializing in oncology and immunology. She previously held leadership positions at Merck Healthcare, where she led global programs from preclinical to late-stage clinical development.
Dr. Höfer's extensive background includes senior roles at Sandoz Biopharmaceuticals, Priaxon AG, and Medigene AG, where she advanced therapeutic programs across various modalities including NBEs, NCEs, nucleotides, and viral and cell-based therapies. She holds a PhD in Pharmacology from the University of Newcastle and has expertise in clinical pharmacology and translational medicine.
The appointment aims to strengthen OSR Holdings' R&D capabilities and accelerate the development of breakthrough therapies. Dr. Höfer will oversee the company's scientific strategy, innovation pipeline, and focus on expanding its footprint in oncology and immunology.